Introduction The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to
validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI is a multisite …

Microglia-mediated synaptic loss contributes to the development of cognitive impairments in
Alzheimer's disease (AD). However, the basis for this immune-mediated attack on synapses …

Gene mining has been a fruitful approach in the study of Alzheimer's disease (AD). As a new
starting point for studying AD, genetic and genomic investigations consistently strive to …

Longitudinal preclinical and clinical studies suggest that Aβ drives neurite and synapse
degeneration through an array of tau-dependent and independent mechanisms. The …

Background Alzheimer's disease (AD) is the most common type of neurodegenerative
disease. Tau pathology is one of the pathological features of AD, and its progression is …

Recently, we and others have found that hyperfiltration-associated increase in
biomechanical forces, namely, tensile stress and fluid flow shear stress (FFSS), can directly …

Background Genome-wide association studies (GWAS) have identified many individual
genes associated with brain imaging quantitative traits (QTs) in Alzheimer's disease (AD) …

Background and purpose Accumulated failures in Alzheimer's disease (AD) clinical trials
have highlighted an urgent need to identify additional biomarkers involved in AD. Recently …

Variants identified in earlier genome-wide association studies (GWAS) on differentiated
thyroid carcinoma (DTC) explain about 10% of the overall estimated genetic contribution …

Abstract A-kinase anchoring protein 79/150 (AKAP79/150) is a crucial scaffolding protein
that positions various proteins at specific synaptic sites to modulate excitatory synaptic …